Gold Coast Health Plan (GCHP) Medi-Cal Clinical Guidelines
Tislelizumab-jsgr (Tevimbra™)

PA Criteria	Criteria Details
Covered Uses (FDA approved indication)	Programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer • In combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1. • As a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2- negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1.
Exclusion Criteria	None
Required Medical Information	Initial – Must meet ALL of the following: • Tumor progress during or after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor for advances unresectable/metastatic ESCC. • Inadequate response, intolerance, or contraindication to nivolumab or pembrolizumab. • Baseline liver enzymes, creatinine, and thyroid function. • Pregnancy testing and advice on contraception are provided to patients of reproductive potential prior to initiating treatment. Renewal: • Continues to meet initial approval criteria Absence of unacceptable toxicities or side effects, including immune-mediated adverse reactions, severe infusion reactions
Age Restriction	18 years and older. 18 to 21 years of age – check CCS eligibility
Prescriber Restrictions	Oncologist or hematologist
Coverage Duration	Initial – 6 months; Renewal – 12 months
Other Criteria/Information	Criteria adapted from DHCS Oct. 2025

HCPCS	Description	Dosing, Units
J9329	Injection, tislelizumab-jsgr, 1mg (Tevimbra) 100mg/10ml single dose vial	• 150 mg every 2 weeks or 200 mg every 3 weeks or 300 mg every 4 weeks or 400 mg every 6 weeks Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle. FL: 12mg/kg IV infusion • Cycles 1 to 3: Days 1, 8, 15, and 22 of each 28-day cycle

	200mg single dose vial	• Cycles 4 to 12: Days 1 and 15 of each 28-day cycle.	

STATUS	DATE REVISED	REVIEW DATE	APPROVED/REVIEWED BY	EFFECTIVE DATE
Created	Jan. 15, 2026	N/A	Yoonhee Kim, Senior Clinical Pharmacist	N/A